-
Monlunabant (INV-202, MRI-1891, or S-MRI-1891) is a
peripherally selective cannabinoid receptor 1
inverse agonist,
discovered as a β-arrestin-2-biased...
- (dronabinol) UR-144 WIN 55,212-2
Yangonin Inverse agonists AM-251 INV-202
Monlunabant Rimonabant Surinabant Taranabant TM-38837
Zevaquenabant Antagonists AM-6545...
- (dronabinol) UR-144 WIN 55,212-2
Yangonin Inverse agonists AM-251 INV-202
Monlunabant Rimonabant Surinabant Taranabant TM-38837
Zevaquenabant Antagonists AM-6545...
- (dronabinol) UR-144 WIN 55,212-2
Yangonin Inverse agonists AM-251 INV-202
Monlunabant Rimonabant Surinabant Taranabant TM-38837
Zevaquenabant Antagonists AM-6545...
- (dronabinol) UR-144 WIN 55,212-2
Yangonin Inverse agonists AM-251 INV-202
Monlunabant Rimonabant Surinabant Taranabant TM-38837
Zevaquenabant Antagonists AM-6545...
- (dronabinol) UR-144 WIN 55,212-2
Yangonin Inverse agonists AM-251 INV-202
Monlunabant Rimonabant Surinabant Taranabant TM-38837
Zevaquenabant Antagonists AM-6545...
- (dronabinol) UR-144 WIN 55,212-2
Yangonin Inverse agonists AM-251 INV-202
Monlunabant Rimonabant Surinabant Taranabant TM-38837
Zevaquenabant Antagonists AM-6545...
- (dronabinol) UR-144 WIN 55,212-2
Yangonin Inverse agonists AM-251 INV-202
Monlunabant Rimonabant Surinabant Taranabant TM-38837
Zevaquenabant Antagonists AM-6545...
- (dronabinol) UR-144 WIN 55,212-2
Yangonin Inverse agonists AM-251 INV-202
Monlunabant Rimonabant Surinabant Taranabant TM-38837
Zevaquenabant Antagonists AM-6545...
- (dronabinol) UR-144 WIN 55,212-2
Yangonin Inverse agonists AM-251 INV-202
Monlunabant Rimonabant Surinabant Taranabant TM-38837
Zevaquenabant Antagonists AM-6545...